Business Context and Reporting Period
This Form 8-K Current Report is filed by Bristol-Myers Squibb Company for the reporting period ending October 31, 2013. The filing primarily addresses a significant debt financing event under Item 8.01 (Other Events).
Key Financial Metrics and Debt Activity
The company executed a debt issuance totaling $1.5 billion in aggregate principal amount. The transaction closed on October 31, 2013. The specific tranches issued are as follows:
- 1.750% Notes due 2019: $500,000,000
- 3.250% Notes due 2023: $500,000,000
- 4.500% Notes due 2044: $500,000,000
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, or overall liquidity positions, as this report focuses exclusively on the debt issuance event.
Material Changes and Transaction Details
The material change reported is the agreement to sell and subsequent closing of the Notes described above. The underwriting agreement was dated October 24, 2013, with representatives including Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., BNP Paribas Securities Corp., Credit Suisse Securities (USA) LLC, and RBS Securities Inc. The Notes were issued pursuant to an Indenture dated June 1, 1993, as supplemented by the Seventh Supplemental Indenture dated October 31, 2013.
Guidance, Risks, and Unusual Items
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard legal disclosures associated with the debt issuance. No unusual items or contingencies are detailed in the text provided.
Investor Verification Checklist
- Verify the total proceeds received from the $1.5 billion note issuance after underwriting discounts.
- Confirm the specific covenants and call provisions within the Seventh Supplemental Indenture (Exhibit 4.1).
- Review the company's updated total debt load and leverage ratios in subsequent quarterly filings (10-Q) to assess the impact of this issuance.
- Check the use of proceeds disclosed in the Registration Statement on Form S-3 (No. 333-182852) referenced in the filing.